Eupraxia Pharmaceuticals (EPRX) Operating Leases (2022 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 5 years of Operating Leases data on file, last reported at $1.8 million in Q1 2026.

• On a quarterly basis, Operating Leases changed N/A year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $1.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $75910.0, up 5.64% from the prior year.
• Operating Leases for Q1 2026 stood at $1.8 million, up from $75910.0 in the prior quarter.
• Over the last five years, Operating Leases for EPRX reached as high as $1.8 million in Q1 2026 and fell as low as $37848.0 in Q1 2024.
• Historically, Operating Leases has averaged $259750.6 across 5 years, with a median of $71859.0 in 2024.
• Across the five-year window, Operating Leases increased 3.92% in 2023 and jumped 34.78% in 2024, its largest moves.
• Year by year, Operating Leases stood at $51303.0 in 2022, then advanced by 3.92% to $53316.0 in 2023, then surged by 34.78% to $71859.0 in 2024, then rose by 5.64% to $75910.0 in 2025, then soared by 2275.57% to $1.8 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $1.8 million in Q1 2026, $75910.0 in Q4 2025, and $94467.0 in Q3 2025.